Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

COX-2 inhibitors.

P M Brooks1, R O Day

  • 1University of Queensland, Royal Brisbane Hospital, Brisbane.

The Medical Journal of Australia
|November 23, 2000
PubMed
Summary
This summary is machine-generated.

New cyclooxygenase-2 (COX-2) inhibitors offer pain relief for arthritis and other conditions. These drugs, including celecoxib and rofecoxib, are as effective as traditional NSAIDs but with fewer gastrointestinal side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: A systematic review.

Transplantation reviews (Orlando, Fla.)·2021
Same author

Trends, determinants and differences in antibiotic use in 68 residential aged care homes in Australia, 2014-2017: a longitudinal analysis of electronic health record data.

BMC health services research·2020
Same author

Towards precision dosing of vancomycin in critically ill patients: an evaluation of the predictive performance of pharmacometric models in ICU patients.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same author

Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2019
Same author

Evaluation of Clinical Relevance of Drug-Drug Interaction Alerts Prior to Implementation.

Applied clinical informatics·2018
Same author

Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM).

European journal of clinical pharmacology·2018
Same journal

Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population.

The Medical journal of Australia·2026
Same journal

Striving for Racial Equity in Oral Cancer Research: A Case Study.

The Medical journal of Australia·2026
Same journal

Progressing Cross-Sector Collaboration for People With Eating Disorders and Higher Weight: Priority Actions From an Expert Roundtable Using a Modified Nominal Group Technique.

The Medical journal of Australia·2026
Same journal

Self-Poisoning With Prazosin and Its Off-Label Use in Australia, 2014-2024: Analysis of NSW Poisons Information Centre Data.

The Medical journal of Australia·2026
Same journal

Drivers of Vaccine Uptake for Aboriginal and Torres Strait Islander Children to Inform Tailored Strategies: A Qualitative Study Exploring Health Service Provider Perspective.

The Medical journal of Australia·2026
Same journal

Four Urgent Actions for the Rights to Culturally Safe Breastfeeding for Aboriginal and Torres Strait Islander Mothers and Babies to Breastfeed in Neonatal Intensive Care Environments.

The Medical journal of Australia·2026
See all related articles

Area of Science:

  • Pharmacology
  • Rheumatology
  • Gastroenterology

Background:

  • Cyclooxygenase-2 (COX-2) inhibitors represent a novel class of non-steroidal anti-inflammatory drugs (NSAIDs).
  • At therapeutic doses, they selectively inhibit prostaglandin production via COX-2, sparing cyclooxygenase-1 (COX-1).
  • Currently, celecoxib (twice daily) and rofecoxib (once daily) are available in Australia.

Purpose of the Study:

  • To review the efficacy and safety of COX-2 inhibitors.
  • To compare their effects with traditional non-selective NSAIDs.

Main Methods:

  • Review of Level 2 evidence regarding COX-2 inhibitors.
  • Analysis of clinical outcomes including pain relief, anti-inflammatory effects, and gastrointestinal toxicity.

Related Experiment Videos

Main Results:

  • COX-2 inhibitors provide rapid pain relief and possess equivalent anti-inflammatory and analgesic effects to standard NSAIDs in osteoarthritis and rheumatoid arthritis.
  • Significantly lower incidences of gastrotoxicity, including ulcers and bleeds, were observed compared to non-selective NSAIDs.
  • Evidence supports their efficacy in various pain models: third-molar extraction, dysmenorrhea, post-orthopaedic surgery pain, and hip/knee osteoarthritis.
  • Adverse effects, such as potential renal dysfunction in compromised patients and interference with antihypertensive agents, appear comparable to non-selective NSAIDs.

Conclusions:

  • COX-2 inhibitors are effective alternatives to traditional NSAIDs for managing pain and inflammation in conditions like osteoarthritis and rheumatoid arthritis.
  • Their key advantage lies in a reduced risk of gastrointestinal complications.
  • Potential renal and cardiovascular adverse effects warrant consideration, similar to non-selective NSAIDs.